MX2021006012A - Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. - Google Patents
Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.Info
- Publication number
- MX2021006012A MX2021006012A MX2021006012A MX2021006012A MX2021006012A MX 2021006012 A MX2021006012 A MX 2021006012A MX 2021006012 A MX2021006012 A MX 2021006012A MX 2021006012 A MX2021006012 A MX 2021006012A MX 2021006012 A MX2021006012 A MX 2021006012A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- substituted amino
- quinazoline derivatives
- receptor antagonists
- adenosine receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En sus muchas modalidades, la presente invención proporciona ciertos derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos de la Fórmula (I): (ver Fórmula), o una sal farmacéuticamente aceptable de los mismos, en donde el anillo A, R1, R2 y R4 son como se definen en la presente, las composiciones farmacéuticas que comprenden uno o más de dichos compuestos (solos y en combinación con uno o más de otros agentes terapéuticamente activos), y métodos para su preparación y uso, solos y en combinación con otros agentes terapéuticos, como antagonistas de los receptores A2a y/o A2b, y su uso en el tratamiento de una variedad de enfermedades, afecciones o trastornos que están mediados, al menos en parte, por el receptor de adenosina A2a y/o el receptor de adenosina A2b.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774069P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/063146 WO2020112706A1 (en) | 2018-11-30 | 2019-11-26 | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006012A true MX2021006012A (es) | 2021-07-06 |
Family
ID=70852081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006012A MX2021006012A (es) | 2018-11-30 | 2019-11-26 | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230054411A1 (es) |
EP (1) | EP3887377A4 (es) |
JP (1) | JP2022511778A (es) |
KR (1) | KR20210097152A (es) |
CN (1) | CN113166158A (es) |
AU (1) | AU2019388872A1 (es) |
BR (1) | BR112021010273A2 (es) |
CA (1) | CA3120331A1 (es) |
MX (1) | MX2021006012A (es) |
WO (1) | WO2020112706A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20210271A (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024118460A1 (en) * | 2022-11-29 | 2024-06-06 | Merck Sharp & Dohme Llc | Adenosine a2a and a2b receptor antagonists, pharmaceutical compositions and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
WO2014101113A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2015027431A1 (en) * | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
CR20210271A (es) * | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso |
-
2019
- 2019-11-26 MX MX2021006012A patent/MX2021006012A/es unknown
- 2019-11-26 BR BR112021010273-6A patent/BR112021010273A2/pt not_active Application Discontinuation
- 2019-11-26 KR KR1020217019799A patent/KR20210097152A/ko unknown
- 2019-11-26 US US17/294,836 patent/US20230054411A1/en active Pending
- 2019-11-26 AU AU2019388872A patent/AU2019388872A1/en not_active Abandoned
- 2019-11-26 EP EP19888675.6A patent/EP3887377A4/en active Pending
- 2019-11-26 CN CN201980078790.6A patent/CN113166158A/zh not_active Withdrawn
- 2019-11-26 CA CA3120331A patent/CA3120331A1/en active Pending
- 2019-11-26 WO PCT/US2019/063146 patent/WO2020112706A1/en unknown
- 2019-11-26 JP JP2021530115A patent/JP2022511778A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230054411A1 (en) | 2023-02-23 |
CA3120331A1 (en) | 2020-06-04 |
CN113166158A (zh) | 2021-07-23 |
AU2019388872A1 (en) | 2021-05-27 |
EP3887377A4 (en) | 2022-08-24 |
JP2022511778A (ja) | 2022-02-01 |
EP3887377A1 (en) | 2021-10-06 |
BR112021010273A2 (pt) | 2021-08-17 |
WO2020112706A1 (en) | 2020-06-04 |
KR20210097152A (ko) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021551196A1 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
ATE424402T1 (de) | Imidazopyridinverbindungen | |
MX2018003186A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer. | |
MX2018004954A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer. | |
MX2007004976A (es) | Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios. | |
MX2016015761A (es) | Derivados de amina de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor. | |
EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
TW200640904A (en) | Quinazoline derivatives | |
MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
MX2022004121A (es) | Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor. | |
MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
MX2021004885A (es) | Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor. | |
PH12017501736A1 (en) | Indole derivatives | |
EA202192092A2 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
EA201600360A2 (ru) | Фармацевтические композиции на основе 9-бутиламино-3,3-диметил-3,4-дигидроакридин-1(2h)-она гидрохлорида для коррекции когнитивных и неврологических нарушений |